Nathella Pavan Kumar1, Kadar Moideen1, Vaithilingam V Banurekha1, Dina Nair2, Subash Babu1,3. 1. National Institutes of Health, National Institute for Research in Tuberculosis, International Center for Excellence in Research, Chennai, India. 2. National Institute for Research in Tuberculosis, Chennai, India. 3. Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: Type 1, type 17, and other proinflammatory cytokines are important in host immunity to tuberculosis (TB) in animal models. However, their role in human immunity to TB is not completely understood. METHODS: To examine the association of proinflammatory cytokines with pulmonary TB (PTB), we examined the plasma levels of type 1 (interferon [IFN]γ and tumor necrosis factor [TNF]α), type 17 (interleukin [IL]-17A and IL-17F), and other proinflammatory (IL-6, IL-12, and IL-1β) cytokines in individuals with PTB, latent TB (LTB), or healthy controls (HC). RESULTS: Individuals with PTB exhibited significantly higher plasma levels of most of the above cytokines compared with LTB or HC individuals. Principal component analysis based on these cytokines could clearly distinguish PTB from both LTB or HC individuals. Pulmonary TB individuals with bilateral or cavitary disease exhibited significantly higher levels of IFNγ, TNFα, IL-17A, and IL-1β compared with those with unilateral or noncavitary disease. Pulmonary TB individuals also exhibited a significant positive relationship between IFNγ, TNFα, and IL-17A levels and bacterial burdens. In addition, PTB individuals with delayed culture conversion exhibited significantly higher levels of IFNγ, TNFα, IL-17A, and IL-1β at baseline. Finally, the plasma levels of all the cytokines examined were significantly reduced after successful chemotherapy. CONCLUSIONS: Therefore, our data demonstrate that PTB is associated with heightened levels of plasma proinflammatory cytokines, which are reversed after chemotherapy. Our data also reveal that proinflammatory cytokines are markers of disease severity, bacterial burden, and delayed culture conversion in PTB.
BACKGROUND: Type 1, type 17, and other proinflammatory cytokines are important in host immunity to tuberculosis (TB) in animal models. However, their role in human immunity to TB is not completely understood. METHODS: To examine the association of proinflammatory cytokines with pulmonary TB (PTB), we examined the plasma levels of type 1 (interferon [IFN]γ and tumor necrosis factor [TNF]α), type 17 (interleukin [IL]-17A and IL-17F), and other proinflammatory (IL-6, IL-12, and IL-1β) cytokines in individuals with PTB, latent TB (LTB), or healthy controls (HC). RESULTS: Individuals with PTB exhibited significantly higher plasma levels of most of the above cytokines compared with LTB or HC individuals. Principal component analysis based on these cytokines could clearly distinguish PTB from both LTB or HC individuals. Pulmonary TB individuals with bilateral or cavitary disease exhibited significantly higher levels of IFNγ, TNFα, IL-17A, and IL-1β compared with those with unilateral or noncavitary disease. Pulmonary TB individuals also exhibited a significant positive relationship between IFNγ, TNFα, and IL-17A levels and bacterial burdens. In addition, PTB individuals with delayed culture conversion exhibited significantly higher levels of IFNγ, TNFα, IL-17A, and IL-1β at baseline. Finally, the plasma levels of all the cytokines examined were significantly reduced after successful chemotherapy. CONCLUSIONS: Therefore, our data demonstrate that PTB is associated with heightened levels of plasma proinflammatory cytokines, which are reversed after chemotherapy. Our data also reveal that proinflammatory cytokines are markers of disease severity, bacterial burden, and delayed culture conversion in PTB.
Authors: Shabaana A Khader; Guy K Bell; John E Pearl; Jeffrey J Fountain; Javier Rangel-Moreno; Garth E Cilley; Fang Shen; Sheri M Eaton; Sarah L Gaffen; Susan L Swain; Richard M Locksley; Laura Haynes; Troy D Randall; Andrea M Cooper Journal: Nat Immunol Date: 2007-03-11 Impact factor: 25.606
Authors: J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun Journal: N Engl J Med Date: 2001-10-11 Impact factor: 91.245
Authors: N P Juffermans; A Verbon; S J van Deventer; H van Deutekom; J T Belisle; M E Ellis; P Speelman; T van der Poll Journal: Infect Immun Date: 1999-08 Impact factor: 3.441
Authors: Ramakrishna Vankayalapati; Benjamin Wizel; Stephen E Weis; Peter Klucar; Homayoun Shams; Buka Samten; Peter F Barnes Journal: Clin Infect Dis Date: 2002-12-10 Impact factor: 9.079
Authors: Monika M Vivekanandan; Ernest Adankwah; Wilfred Aniagyei; Isaac Acheampong; Augustine Yeboah; Joseph F Arthur; Millicent N K Lamptey; Mohammed K Abass; Amidu Gawusu; Francis Kumbel; Francis Osei-Yeboah; Linda Batsa Debrah; Dorcas O Owusu; Alexander Debrah; Ertan Mayatepek; Julia Seyfarth; Richard O Phillips; Marc Jacobsen Journal: Infection Date: 2022-06-27 Impact factor: 3.553
Authors: Wenxi Xu; Laura M Snell; Mengdi Guo; Giselle Boukhaled; Bethany L Macleod; Ming Li; Michael V Tullius; Cynthia J Guidos; Ming-Sound Tsao; Maziar Divangahi; Marcus A Horwitz; Jun Liu; David G Brooks Journal: Immunity Date: 2021-01-29 Impact factor: 31.745
Authors: Noha A Hassuna; Mohamed El Feky; Aliae A R Mohamed Hussein; Manal A Mahmoud; Naglaa K Idriss; Sayed F Abdelwahab; Maggie A Ibrahim Journal: PLoS One Date: 2021-01-07 Impact factor: 3.240
Authors: Arista Nienaber; Jeannine Baumgartner; Robin C Dolman; Mumin Ozturk; Lizelle Zandberg; Frank E A Hayford; Frank Brombacher; Renee Blaauw; Suraj P Parihar; Cornelius M Smuts; Linda Malan Journal: Nutrients Date: 2020-09-22 Impact factor: 5.717